These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 38414439

  • 1. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
    Li DY, Liu X, Huang JY, Hang WL, Yu GR, Xu Y.
    Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
    [Abstract] [Full Text] [Related]

  • 2. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE, Kahn N, Wälscher J, Sarmand N, Polke M, Lars K, Eichinger M, Heussel CP, Palmucci S, Sambataro FM, Sambataro G, Sambataro D, Vancheri C, Kreuter M.
    BMC Pulm Med; 2019 Nov 12; 19(1):213. PubMed ID: 31718637
    [Abstract] [Full Text] [Related]

  • 3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN.
    Drugs; 2021 Apr 12; 81(5):575-586. PubMed ID: 33765296
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI, Park H, Park S, Shin JY, Kim YH.
    BMC Pulm Med; 2023 Mar 22; 23(1):98. PubMed ID: 36949407
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
    Gibson CD, Kugler MC, Deshwal H, Munger JS, Condos R.
    Lung; 2020 Aug 22; 198(4):597-608. PubMed ID: 32591895
    [Abstract] [Full Text] [Related]

  • 9. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U, Weber B, Magnusson MO, Freiwald M.
    Respir Med; 2021 Aug 22; 180():106369. PubMed ID: 33798871
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
    Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M, INBUILD Trial Investigators.
    Respir Res; 2021 Mar 16; 22(1):84. PubMed ID: 33726766
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD.
    Chong WH, Agrawal D, Tan ZY, Venkateswaran S, Tan AYY, Tan CY, Ling NCA, Tay NSWT.
    Heart Lung; 2024 Mar 16; 68():242-253. PubMed ID: 39089077
    [Abstract] [Full Text] [Related]

  • 19. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H, Zhao Y, Li Z, Kang J.
    Ther Adv Respir Dis; 2020 Mar 16; 14():1753466620963015. PubMed ID: 33070705
    [Abstract] [Full Text] [Related]

  • 20. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
    Shumar JN, Chandel A, King CS.
    J Clin Med; 2021 May 25; 10(11):. PubMed ID: 34070297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.